Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).
Condition or disease
Graft Versus Host Disease
Drug: recombinant human keratinocyte growth factor
Phase 1Phase 2
Completion date provided represents the completion date of the grant per OOPD records
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
3 Years to 65 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6 HLA idential sibling donor